Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.
NCT00290901
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- The subject presents with duration of chronic low back pain of > 3 months requiring regular use of analgesics (> 4 days/week), except for acetaminophen which cannot have been the sole analgesic used.
- The subject has chronic low back pain, which is neurologic in etiology (i.e.,
radiculopathy, neuropathy, myelopathy)
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Loma Linda, California
- Helsinki,
- Phoenix, Arizona
- Scottsdale, Arizona
- Tucson, Arizona
- Little Rock, Arkansas
- Anaheim, California
- La Mesa, California
- Long Beach, California
- Oceanside, California
- Paramount, California
- Sacramento, California
- San Francisco, California
- San Luis Obispo, California
- Tustin, California
- Vista, California
- Boulder, Colorado
- Colorado Springs, Colorado
- Denver, Colorado
- Cos Cob, Connecticut
- Washington, District of Columbia
- Miami, Florida
- Pembroke Pines, Florida
- West Palm Beach, Florida
- Decatur, Georgia
- Woodstock, Georgia
- Libertyville, Illinois
- Morton Grove, Illinois
- Arkansas City, Kansas
- Overland Park, Kansas
- Wichita, Kansas
- Madisonville, Kentucky
- Baltimore, Maryland
- Wheaton, Maryland
- Jackson, Mississippi
- Kansas City, Missouri
- St. Louis, Missouri
- Omaha, Nebraska
- Brooklyn, New York
- New York, New York
- Rochester, New York
- Raleigh, North Carolina
- Medford, Oregon
- Portland, Oregon
- Camp Hill, Pennsylvania
- Duncansville, Pennsylvania
- Charleston, South Carolina
- Columbia, South Carolina
- Johnson City, Tennessee
- New Tazewell, Tennessee
- Austin, Texas
- San Angelo, Texas
- San Antonio, Texas
- Arlington, Virginia
- Danville, Virginia
- Rio Piedras,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain. | |||
Official Title ICMJE | A Six Week Double-Blind, Randomized, Multicenter Comparison Study of the Analgesic Effectiveness of Celecoxib 200 mg BID Compared to Tramadol Hydrochloride 50 mg QID in Subjects With Chronic Low Back Pain | |||
Brief Summary | This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | |||
Condition ICMJE | Back Pain | |||
Intervention ICMJE |
| |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 754 | |||
Original Enrollment ICMJE | Same as current | |||
Study Completion Date ICMJE | Not Provided | |||
Actual Primary Completion Date | December 2006 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Puerto Rico, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00290901 | |||
Other Study ID Numbers ICMJE | A3191165 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | March 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |